Email
Password
Remember meForgot password?
    Log in with Twitter

article imageLowering cholesterol thanks to artificial prebiotics

By Tim Sandle     Jun 21, 2017 in Health
Budapest - A new study indicates that a naturally synthesized prebiotic can target and increase the growth of bacteria in the human gut which lead to a reduction in cholesterol levels. The research comes from the University of Reading in the U.K.
The university has worked in conjunction with a company called OptiBiotix Health. The company sets out to discover and develop microbial strains, compounds and formulations, which can modulate human health.
The findings indicate that a naturally synthesized prebiotic can trigger the growth of a cholesterol-reducing probiotic bacterium called Lactobacillus plantarum. L. plantarum is commonly found in many fermented food products including sauerkraut, pickles, brined olives, Korean kimchi, Nigerian Ogi, sourdough, and other fermented plant material, and also some cheeses, fermented sausages, and stockfish.
In addition the cholesterol-reduction activity of the bacterium appears to be enhanced. Probiotics are defined as live microorganisms that are believed to provide health benefits when consumed. The chemical acts as a prebiotic, leading to the bacterial activity. Prebiotics are food ingredients that induce the growth or activity of beneficial microorganisms. Often prebiotics are a special type of complex carbohydrate found in a variety of foods and food supplements that naturally feed the ‘good’ types of bacteria residing in our guts.
The research forms part of a relatively new field called microbiome modulation and the researchers state that this is the first time a study has demonstrated the formulation of a synergistic synthesized prebiotic that can increase the beneficial health effect of a particular probiotic. The microbiome, as Pharmaceutical Microbiology Resources describes, is the collection of organisms and their genetic interactions within a given ecological niche (in this case, the human gut).
The synthesized prebiotic was developed using reverse enzyme technology. The prebiotic has been named LPGOS. The strain of Lactobacillus plantarum, which was selected from in excess of 4,000 candidate organisms, is coded LPLDL®.
Based on earlier studies which showed that the Lactobacillus plantarum strain can reduce ‘bad’ (LDL) cholesterol by up to 13.9 percent and to reduce blood pressure by up to 5.1 percent, the research found that when LPLDL® is combined with the LPGOS prebiotic, this led to the cholesterol lowering effect improving threefold, when measured across a 24-hour period.
The outcome of the research is that the development of a new form of healthcare supplement should be possible, as a combination prebiotic and probiotic. The working name for this is ‘OptiBiotic’.
The study outcomes have recently been presented by Dr Sofia Kolida to the International Scientific Conference on Probiotics and Prebiotics which took place in Budapest, Hungary on June 2017.
More about Cholesterol, microbiome, Bacteria, Probiotics, prebiotics
More news from
Latest News
Top News